<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03696303</url>
  </required_header>
  <id_info>
    <org_study_id>18-0737</org_study_id>
    <nct_id>NCT03696303</nct_id>
  </id_info>
  <brief_title>Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala</brief_title>
  <official_title>Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective case-control study aims to evaluate the utility and establish laboratory
      thresholds for a multi-serotype urine antigen test for the diagnosis of pneumococcal
      community acquired pneumonia in children 5 years of age or younger in Guatemala.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary antigen detection cut-points for invasive S. pneumoniae disease</measure>
    <time_frame>Within 48 hours</time_frame>
    <description>To determine Cut-Points to discriminate a positive or negative urine antigen test that differentiates invasive disease versus the carriage state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of S. pneumoniae serotypes using Urinary antigen detection assay</measure>
    <time_frame>Within 48 hours</time_frame>
    <description>To determine the sensitivity and specificity of the Luminex xMPA pneumococcal UAD in the identification of S. pneumoniae serotypes (PCV13 serotypes) in children with radiologically confirmed CAP</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">960</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <condition>Streptococcus Pneumoniae Infection</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Suspected community-acquired bacterial pneumonia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy children, age-matched to enrolled cases</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urinary antigen detection assay</intervention_name>
    <description>Screening for Ag level in S. pneumoniae urinary antigen detection assay.</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine Blood Nasopharyngeal swab samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children 5 years of age or younger with either community-acquired pneumonia (cases) or
        health children (controls).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        CASES:

        Inclusion Criteria:

          -  Age older than 1 month (31 days) and up to 71 months and 28 days.

          -  Diagnosis of radiologically confirmed pneumonia per WHO criteria in the ED or hospital
             within 48 hours of hospital admission

          -  Signed informed consent by parents or legal guardian to participate in the study

        Exclusion Criteria:

          -  Known immunodeficiency

          -  Major congenital malformation (e.g., hemodynamically compromised congenital heart
             malformation or any malformation leading to recurrent pneumonia) or serious chronic
             disorder

          -  Significant neurological disorder

          -  Hospitalization within the previous 30 days for pneumonia or respiratory infection

          -  Use of parenteral antibiotics for current illness (leading to diagnosis of pneumonia)

          -  Transferred to the study hospital after already being hospitalized at a different
             location for â‰¥ 48 hours

        CONTROLS:

        Inclusion Criteria:

          -  Age 1 to 71 months and signed informed consent by parents or legal guardian

        Exclusion Criteria:

          -  Known immunodeficiency

          -  Major congenital malformation (e.g., hemodynamically compromised congenital heart
             malformation or any malformation leading to recurrent pneumonia) or serious chronic
             disorder

          -  Significant neurological disorder

          -  Fever or suspicion of community-acquired pneumonia or other respiratory infectious
             disease (symptoms of cough, congestion, tachypnea, indrawing, etc.)

          -  Hospitalization within the previous 30 days for pneumonia or respiratory infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>31 Days</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin Asturias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado - Anschutz Medical Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara R Saporta-Keating, MD</last_name>
    <phone>720-777-1084</phone>
    <email>sara.saporta-keating@childrenscolorado.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Olson, MD</last_name>
    <phone>720-724-9558</phone>
    <email>Daniel.Olson@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Regional Cuilapa</name>
      <address>
        <city>Cuilapa</city>
        <state>Santa Rosa</state>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diva M Calvimontes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Diva M Calvimontes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General IGSS</name>
      <address>
        <city>Guatemala</city>
        <zip>01009</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Recinos, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sonia Perez, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Fabio Recinos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Perez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Roosevelt</name>
      <address>
        <city>Guatemala</city>
        <zip>01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Melgar, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mario A Melgar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Guatemala</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Community-acquired</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Urine antigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

